In one study, SATB2 expression was diffuse and strongly positive in 96.8% of adenocarcinomas of colorectal origin and positive in only 6.7%, 0%, and 4.2% of adenocarcinomas of esophagus, stomach, and pancreas, respectively [15]. This evidence concerns the gene SATB2 and adenocarcinoma.